Randomized trial of low-dose peginterferon α-2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1

Yoshiaki Iwasaki, Ryo Ichi Okamoto, Yasushi Ishii, Yasuyuki Araki, Noriaki Hashimoto, Kazuhide Yamamoto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Elderly patients with chronic hepatitis C cannot tolerate standard combination therapy of peginterferon and ribavirin, which remains the backbone of therapy in many countries, including Japan. The efficacy and safety of low-dose peginterferon α-2b in combination with low and escalating doses of ribavirin in older patients with high viral load genotype 1 were investigated in this randomized controlled trial. Thirty-two patients (age ≥60 years) were randomized into standard (group 1) or low (group 2) doses of peginterferon α-2b in combination with low and escalating doses of ribavirin. Patients were evaluated for safety and efficacy of treatment. There was a higher virological response rate in group 1 than in group 2. However, the response in men was higher than in women in the early treatment phase and 24 weeks after treatment (P=0.008). There was no significant difference between the two groups in the virological response rate in men and women. Completion of therapy was higher in group 2 than in group 1 (31% vs. 13%, P=0.200). Dose modification of ribavirin was less frequent in group 2 than in group 1 (69% vs. 88%, P=0.200). These data suggest that combination therapy with low-dose peginterferon plus low and escalating doses of ribavirin may be safer in older patients than that with standard dose peginterferon, without impairing the treatment response.

Original languageEnglish
Pages (from-to)2082-2089
Number of pages8
JournalJournal of Medical Virology
Volume87
Issue number12
DOIs
Publication statusPublished - Dec 1 2015

Keywords

  • Adverse event
  • Dose modification
  • Sustained virological response
  • Treatment discontinuation

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Randomized trial of low-dose peginterferon α-2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1'. Together they form a unique fingerprint.

  • Cite this